Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE on NYSE American) on January 8, 2024. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the appointment of a director and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size to four members.
- New Appointment: Steven Mintz was appointed as a director to fill the new vacancy.
- Committee Assignments: Mr. Mintz was appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
Guidance, Outlook, and Compensation Details
The filing includes standard forward-looking statement disclaimers but provides no specific business guidance or outlook. It details the compensatory arrangements for the new director:
- Cash Compensation: Mr. Mintz will receive a prorated cash fee of $34,331 for director services and $9,809 for serving as Chair of the Audit Committee for the 2024 fiscal year.
- Equity Compensation: Mr. Mintz was granted options to purchase 63,756 shares of AgeX common stock under the AgeX Equity Incentive Plan.
- Vesting and Payment: Cash fees and stock options vest in quarterly installments through December 31, 2024, contingent upon continued service.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 63,756 new stock options granted.
- Review the full text of the AgeX Equity Incentive Plan to understand option exercise prices and terms.
- Confirm the current composition of the Board and the specific roles of the Audit, Compensation, and Governance Committees.
- Check subsequent filings for any updates to the company's liquidity position, as this 8-K does not contain financial statements.